Home » Stocks » TTNP

Titan Pharmaceuticals, Inc. (TTNP)

Stock Price: $2.34 USD -0.01 (-0.43%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Pre-market: $2.20 -0.14 (-5.98%) May 11, 8:41 AM
Market Cap 22.19M
Revenue (ttm) 4.84M
Net Income (ttm) -18.24M
Shares Out 3.77M
EPS (ttm) -4.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $2.34
Previous Close $2.35
Change ($) -0.01
Change (%) -0.43%
Day's Open 2.35
Day's Range 2.22 - 2.37
Day's Volume 122,652
52-Week Range 2.15 - 14.06

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ --  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended Decembe...

1 month ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potenc...

3 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institut...

3 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 rever...

5 months ago - PRNewsWire

The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has increased by 34.75% from $0.13 per share to $0.17 per share. This is an explanation of why it happened.

5 months ago - Pulse2

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended September 30...

5 months ago - PRNewsWire

Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.

Other stocks mentioned: CIDM, DVAX, NEOS, NOK, RYCEY, WTRH
6 months ago - InvestorPlace

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a price of $0....

6 months ago - PRNewsWire

Titan Pharmaceuticals (TTNP) is making news on Wednesday after announcing a deal with JT Pharma to acquire one of its assets. The post Titan Pharmaceuticals News: 8 Things for TTNP Stock Investors to Kn...

6 months ago - InvestorPlace

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders approved th...

7 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

7 months ago - PRNewsWire

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

8 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 8, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today urged its stockholders to vote "FOR" an amendment to its certificate...

10 months ago - PRNewsWire

SAN FRANCISCO, June 24, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a co-promotion partnership with Indegene Inc. ...

10 months ago - PRNewsWire

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the first quarter ended March 31, 202...

11 months ago - PRNewsWire

In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.

Other stocks mentioned: ALIM, CPIX, OSG, RRTS
1 year ago - Investopedia

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

On Wednesday, August 14, Titan Pharmaceuticals (NASDAQ: TTNP) will release its latest earnings report.

1 year ago - Benzinga

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About TTNP

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment ... [Read more...]

Industry
Biotechnology
IPO Date
Jan 18, 1996
Stock Exchange
NASDAQ
Ticker Symbol
TTNP
Full Company Profile

Financial Performance

In 2020, TTNP's revenue was $4.84 million, an increase of 85.72% compared to the previous year's $2.61 million. Losses were -$18.24 million, 10.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for TTNP stock is "Buy" and the 12-month stock price forecast is 7.00.

Price Target
$7.00
Analyst Consensus: Buy